Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Current Leases (2019 - 2022)

Moleculin Biotech's Current Leases history spans 4 years, with the latest figure at $116000.0 for Q4 2022.

  • Quarterly results put Current Leases at $116000.0 for Q4 2022, up 20.83% from a year ago — trailing twelve months through Dec 2022 was $116000.0 (up 20.83% YoY), and the annual figure for FY2022 was $116000.0, up 20.83%.
  • Current Leases for Q4 2022 was $116000.0 at Moleculin Biotech, up from $112000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $122000.0 in Q1 2021 to a low of $77000.0 in Q1 2022.
  • The 4-year median for Current Leases is $112000.0 (2022), against an average of $106222.2.
  • Peak annual rise in Current Leases hit 20.83% in 2022, while the deepest fall reached 36.89% in 2022.
  • Year by year, Current Leases stood at $103000.0 in 2019, then rose by 14.56% to $118000.0 in 2020, then fell by 18.64% to $96000.0 in 2021, then rose by 20.83% to $116000.0 in 2022.
  • According to Business Quant data, Current Leases over the past three periods came in at $116000.0, $112000.0, and $98000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.